13 Sep DOJ Pulls the Plug on Biden’s Cannabis Research & Hemp Testing
Big moves are happening in D.C., and they could hit home for folks dealing with cannabis, hemp, or just trying to live freely. The U.S. Department of Justice just yanked a handful of proposed rules from the Biden administration — rules that many in our community were banking on. Here’s the lowdown.
What Just Went Down
- The Medical Marijuana and Cannabidiol Research Expansion Act (passed 2022) had rules in the works to smooth out research. Those rules are now out.
- A proposed regulation that would’ve let labs test hemp (legally compliant hemp under the Farm Bill) without registering with the DEA. That waiver? Gone.
The reason? The DOJ says it’s all part of their “deregulation initiative” and a rethinking of priorities. Sounds bureaucratic — and it is. But the implications ripple.
One thing to note: despite all this, the bigger proposal to reschedule cannabis down the line is still alive (for now).
Why You Should Care
If you’re part of the cannabis or hemp world — patient, grower, processor, advocate — here’s where this gets real:
- Hindered Research = Slower Progress
Without those easier research pathways, getting serious studies off the ground just got harder. Finding out what works, what doesn’t, how to dose, what side effects are real — that kind of stuff could be pushed back. - Testing Headaches for Hemp Businesses
Hemp is legal (when it meets federal criteria), but testing it just got more complicated. Now labs still need DEA registration even if they’re only dealing with hemp. That’s more red tape, more cost, fewer labs willing or able to do it. Delays, higher prices, possible shutdowns. - Uncertainty Everywhere
When rules disappear, chaos tends to fill the space. Businesses don’t know what to follow, researchers don’t know what approvals they need, and patients may end up waiting for new treatments. No one likes working blind. - Patient Risks
Less research = fewer novel therapies, less clarity on safety. Hemp’s wellness side (CBD, etc.) could suffer too, since testing is critical to ensure products are safe and accurate.
What Still Might Happen
- The rescheduling process is still on the table. Trump has said he’ll address it; when and how remain open questions.
- Laws passed by Congress, like the Research Expansion Act, might force the DOJ to do more than just pull proposals. There’s potential for legislative or legal pushback.
- New regulations could still be proposed, or older ones enforced differently. It’s not over yet.
What Chillum Should Watch
Here in our scene, we can’t just sit back. Here are some things to keep eyes on, and maybe act on:
- Lab access locally: If federal rules burden labs too much, maybe state or regional labs can pick up the slack. But they need support, funding, and legal breathing room.
- Speak up: Whenever there are public comment opportunities, let’s use them. Advocates, patients, small business owners — your voice matters.
- Track your reps: See how Florida politicians respond. Push them to defend the right to research, the right to safe products, and the rights of patients.
- Support grassroots research: Sometimes the community has to lead. Universities, local clinics, nonprofits — these might be safer venues for cannabis/hemp research if federal avenues get too tangled.
Our Take
This pullback by the DOJ is a setback. It messes with clarity, momentum, and for many people, livelihoods. But it’s not a full stop. There’s still fight left — for better rules, for rescheduling, for protecting access and safety.
At Chillum, we’ll keep reporting, organizing, and pushing for what should be the baseline: honest research, free movement for hemp, and respect for people depending on cannabis — medically, creatively, spiritually.
No Comments